Storia in 8 fonti

Melanoma Vaccine Halves Risk of Recurrence, Metastasis Over 5 Years

Adjuvant approach will need confirmation from ongoing phase III trial, says expert

Raccontata danpr.orgnbcnews.commorningstar.comansa.itindependent.co.ukforbes.comliberoquotidiano.itmedpagetoday.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mesi fa

Melanoma Vaccine Halves Risk of Recurrence, Metastasis Over 5 Years

Adjuvant approach will need confirmation from ongoing phase III trial, says expert

originale

nbcnews.com1 mesi fa

A personalized vaccine for melanoma cut the risk of cancer returning after five years

If the vaccine is effective in a late-stage trial, it would be “paradigm-shifting,” one expert said.

Leggi questa versione → originale

morningstar.com1 mesi fa

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in…

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a…

Leggi questa versione → originale

npr.org1 mesi fa

A cancer vaccine made just for you. mRNA is back and it's fighting melanoma

A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with Keytruda, an immunotherapy drug.

Leggi questa versione → originale

independent.co.uk1 mesi fa

Breakthrough melanoma vaccine would slash risk of the deadly cancer returning

An estimated 112,000 new melanoma cases and 8,500 deaths are expected this year

Leggi questa versione → originale

ansa.it1 mesi fa

Melanoma, a 5 anni vivo il 92% dei pazienti trattato con il vaccino personalizzato - Focus Tumore news -…

Vaccino mRNA personalizzato contro melanoma: 92,2% sopravvivenza a 5 anni vs 71,3%, riduce del 59% il rischio metastasi. Il modello di genomic personalization si replicherà su polmone e tumori ad alta mutazione, trasformando precision medicine in standard terapeutico.

Leggi questa versione → originale

Timeline cronologica

1. lunedì 1 giugno 2026·npr.org
   

   A cancer vaccine made just for you. mRNA is back and it's fighting melanoma

   A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in combination with Keytruda, an immunotherapy drug.

2. lunedì 1 giugno 2026·nbcnews.com
   

   A personalized vaccine for melanoma cut the risk of cancer returning after five years

   If the vaccine is effective in a late-stage trial, it would be “paradigm-shifting,” one expert said.

3. lunedì 1 giugno 2026·morningstar.com
   

   Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage…

   At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction…

4. lunedì 1 giugno 2026·ansa.it
   

   Melanoma, a 5 anni vivo il 92% dei pazienti trattato con il vaccino personalizzato - Focus Tumore news - Ansa.it

   Dal congresso mondiale di oncologia ASCO in corso a Chicago arriva una importante conferma sull'efficacia del vaccino a mRna contro il melanoma, la cui sperimentazione è iniziata…

5. lunedì 1 giugno 2026·independent.co.uk
   

   Breakthrough melanoma vaccine would slash risk of the deadly cancer returning

   An estimated 112,000 new melanoma cases and 8,500 deaths are expected this year

6. martedì 2 giugno 2026·forbes.com
   

   New Study Shows How mRNA Vaccines Could Transform Cancer Treatment

   A doctor breaks down a new study on how mRNA vaccines in melanoma research could transform treatment and survival for cancer patients

7. martedì 2 giugno 2026·liberoquotidiano.it
   

   Melanoma, il vaccino ad hoc: crolla del 49% il rischio recidiva | Libero Quotidiano.it

   Un vaccino, combinato all'immunoterapia, ha dimostrato una clamorosa efficacia nell'evitare il rischio di una recidiva di un melanom...

8. martedì 2 giugno 2026·medpagetoday.com
   

   Melanoma Vaccine Halves Risk of Recurrence, Metastasis Over 5 Years

   Adjuvant approach will need confirmation from ongoing phase III trial, says expert